Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the future

[1]  Douglas G. Altman,et al.  Methodological challenges in the evaluation of prognostic factors in breast cancer , 2004, Breast Cancer Research and Treatment.

[2]  David R. Jones,et al.  A systematic review and evaluation of the use of tumour markers in paediatric oncology: Ewing's sarcoma and neuroblastoma. , 2003, Health technology assessment.

[3]  David R. Jones,et al.  A systematic review of molecular and biological markers in tumours of the Ewing's sarcoma family. , 2003, European journal of cancer.

[4]  L. Stewart,et al.  Effects of adjusting for censoring on meta-analyses of time-to-event outcomes. , 2002, International journal of epidemiology.

[5]  N. Brünner,et al.  Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. , 2002, Journal of the National Cancer Institute.

[6]  P C Lambert,et al.  A comparison of summary patient-level covariates in meta-regression with individual patient data meta-analysis. , 2002, Journal of clinical epidemiology.

[7]  T. Conroy,et al.  [Standards, options and recommendations for tumor markers in colorectal cancer]. , 2002, Bulletin du cancer.

[8]  J. Watine,et al.  [Unresected colorectal liver metastases: prognostic value of laboratory variables]. , 2001, Gastroenterologie clinique et biologique.

[9]  J. Pignon,et al.  Individual patient-versus literature-based meta-analysis of survival data: time to event and event rate at a particular time can make a difference, an example based on head and neck cancer. , 2001, Controlled clinical trials.

[10]  A. Hijdra,et al.  Systematic review of prediction of poor outcome in anoxic-ischaemic coma with biochemical markers of brain damage , 2001, Intensive Care Medicine.

[11]  P. Warde,et al.  Does age influence the behaviour of localized prostate cancer? , 2001, BJU international.

[12]  D J Hutchon,et al.  Publishing raw data and real time statistical analysis on e-journals , 2001, BMJ : British Medical Journal.

[13]  Douglas G. Altman,et al.  Systematic Reviews in Health Care , 2001 .

[14]  Alex J. Sutton,et al.  Methods for Meta-Analysis in Medical Research , 2000 .

[15]  D. Stram,et al.  Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M Schumacher,et al.  Modelling the effects of standard prognostic factors in node-positive breast cancer , 1999, British Journal of Cancer.

[17]  M Blettner,et al.  Traditional reviews, meta-analyses and pooled analyses in epidemiology. , 1999, International journal of epidemiology.

[18]  M. Parmar,et al.  Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. , 1998, Statistics in medicine.

[19]  F. Berthold,et al.  The current contribution of molecular factors to risk estimation in neuroblastoma patients. , 1997, European journal of cancer.

[20]  J. Mann,et al.  The United Kingdom Children's Cancer Study Group--the first 20 years of growth and development. , 1997, European journal of cancer.

[21]  Y. Ohashi,et al.  Prognostic value of preoperative immunosuppressive acidic protein in patients with gastric carcinoma: Findings from three independent clinical trials , 1996 .

[22]  Y. Ohashi,et al.  Prognostic value of preoperative immunosuppressive acidic protein in patients with gastric carcinoma. Findings from three independent clinical trials. Tumor Marker Committee for the Study Group of Immunochemotherapy with PSK for Gastric Cancer. , 1996, Cancer.

[23]  L. Stewart,et al.  Practical methodology of meta-analyses (overviews) using updated individual patient data. Cochrane Working Group. , 1995, Statistics in medicine.

[24]  D. G. Altman,et al.  Review of survival analyses published in cancer journals. , 1995, British Journal of Cancer.

[25]  W. Sauerbrei,et al.  Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. , 1994, Journal of the National Cancer Institute.

[26]  M. Parmar,et al.  Meta-analysis of the literature or of individual patient data: is there a difference? , 1993, The Lancet.

[27]  L. Rushton,et al.  Oral contraceptive use and breast cancer risk: A meta‐analysis of variations with age at diagnosis, parity and total duration of oral contraceptive use , 1992, British journal of obstetrics and gynaecology.

[28]  J. Fleiss,et al.  Meta-analysis in epidemiology, with special reference to studies of the association between exposure to environmental tobacco smoke and lung cancer: a critique. , 1991, Journal of clinical epidemiology.